On May 14, 2020 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infections, reported that it will present data on AGEN1181 at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) upcoming ASCO (Free ASCO Whitepaper)2020 Virtual Scientific Program to be held May 29-31, 2020 (Press release, Agenus, MAY 14, 2020, View Source [SID1234557979]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AGEN1181 is a multifunctional Fc-engineered next generation anti-CTLA-4 antibody which has been designed to improve upon the safety and efficacy shown with first-generation CTLA-4 antibodies.
The virtual presentation will be made by Dr. Steven J. O’Day, the Executive Director of the John Wayne Cancer Institute and Cancer Clinic, and Director of Providence Los Angeles Regional Research.
Abstract:
TPS3157
Title:
AGEN1181, A Clinical Stage Fc-engineered anti-CTLA-4 Antibody with Improved Therapeutic Potential for the Treatment of Patients with Advanced Malignancies
Presenter:
Dr. Steven J. O’Day
Session:
Developmental Therapeutics—Immunotherapy
Date/Time:
May 29, 2020/8:00-11:00AM ET
Presentations will be available for on-demand viewing online at View Source beginning on May 29, 2020 at 8:00AM ET.